Endoscopic Sleeve Gastroplasty Combined With GERDx Endoscopic Full-Thickness Plication for Obesity-Associated Mechanical GERD: A Dual-Mechanism Endoscopic Case Series
Abstract
ABSTRACT Obesity-associated gastroesophageal reflux disease (GERD) is often driven by mechanical factors including increased intra-abdominal pressure, hiatal hernia, and gastroesophageal junction dysfunction. Endoscopic sleeve gastroplasty (ESG) reduces gastric volume and intragastric pressure, whereas endoscopic full-thickness plication (eFTP) reinforces the antireflux barrier. However, data on the intentional combination of these interventions remain limited. This retrospective case series included 9 patients with overweight or obesity and proton pump inhibitor-refractory GERD who underwent same-session ESG and GERDx eFTP at a tertiary endoscopy center. eFTP was performed first, followed by ESG during the same session. All procedures were completed successfully without adverse events. Follow-up (1 month–2 years) demonstrated weight loss, improvement in reflux symptoms, and reduced proton pump inhibitor use. Repeat physiologic testing in selected patients showed improvement in DeMeester scores and esophageal acid exposure. Combined ESG and GERDx eFTP may represent a minimally invasive strategy addressing both intragastric pressure and gastroesophageal junction dysfunction in obesity-associated GERD.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 9 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.